Future Oncology : Impact Factor & More
eISSN: 1744-8301pISSN: 1479-6694
Share this on:
Key Metrics
CiteScore 
4.9
Impact Factor
< 5
SNIP
0.82
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Future Oncology
Future Oncology Journal Specifications
| Overview | |
| Publisher | FUTURE MEDICINE LTD |
| Language | English |
| Frequency | Fortnightly |
| General Details | |
| Language | English |
| Frequency | Fortnightly |
| Publication Start Year | 2005 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Future Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Future Oncology
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.
- 26 Nov 2025
- Future oncology (London, England)
LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.
- 24 Nov 2025
- Future oncology (London, England)
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract.
- 23 Nov 2025
- Future oncology (London, England)
Combination of pan-immune-inflammation value and frailty index predicts the outcomes of elderly nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
- 23 Nov 2025
- Future oncology (London, England)
Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study.
- 21 Nov 2025
- Future oncology (London, England)
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
- 21 Nov 2025
- Future oncology (London, England)
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.
- 26 Nov 2025
- Future oncology (London, England)
LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.
- 24 Nov 2025
- Future oncology (London, England)
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract.
- 23 Nov 2025
- Future oncology (London, England)
Combination of pan-immune-inflammation value and frailty index predicts the outcomes of elderly nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
- 23 Nov 2025
- Future oncology (London, England)
Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study.
- 21 Nov 2025
- Future oncology (London, England)
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
- 21 Nov 2025
- Future oncology (London, England)
FAQs on Future Oncology
How long has Future Oncology been actively publishing? 
What is the publishing frequency of Future Oncology?
How many articles did Future Oncology publish last year?
What is the eISSN & pISSN for Future Oncology?
What is Citescore for Future Oncology?
What is SNIP score for Future Oncology?
Who is the publisher of Future Oncology?
